T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35245466.
- Also identified by DOI 10.1016/j.stem.2022.02.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fibrosis, or chronic fibroblast activation and extracellular matrix deposition, underlies most cardiovascular diseases and remains challenging to target therapeutically. Reported in Science by Rurik et al., modified mRNA technology can reprogram endogenous T cells into fibroblast-ablating CAR-Ts in mouse hearts, offering a promising and tractable immunotherapy approach for tackling fibrosis.
Medical subject headings
- Immunotherapy
- T-Lymphocytes